journal
https://read.qxmd.com/read/33844595/pembrolizumab-in-patients-with-metastatic-breast-cancer-with-high-tumor-mutational-burden-results-from-the-targeted-agent-and-profiling-utilization-registry-tapur-study
#1
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra, Carmen J Calfa, Maged F Khalil, Eugene R Ahn, Timothy L Cannon, Pamela Crilley, Julie G Fisher, Derrick S Haslem, Sagun Shrestha, Kaitlyn R Antonelli, Nicole L Butler, Sasha L Warren, Andrew L Rygiel, Shamika Ranasinghe, Suanna S Bruinooge, Richard L Schilsky
PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS: Patients with advanced mBC received standard doses of either 2 mg/kg or 200 mg infusions of pembrolizumab every 3 weeks...
April 12, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33844589/did-the-randomized-phase-iii-keynote-181-study-of-pembrolizumab-for-esophageal-cancer-yield-negative-or-positive-results
#2
LETTER
Hironobu Minami, Naomi Kiyota, Takashi Omori
No abstract text is available yet for this article.
April 12, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33835855/impact-of-previously-unrecognized-hla-mismatches-using-ultrahigh-resolution-typing-in-unrelated-donor-hematopoietic-cell-transplantation
#3
Neema P Mayor, Tao Wang, Stephanie J Lee, Michelle Kuxhausen, Cynthia Vierra-Green, Dominic J Barker, Jeffrey Auletta, Vijaya R Bhatt, Shahinaz M Gadalla, Loren Gragert, Yoshihiro Inamoto, Gerald P Morris, Sophie Paczesny, Ran Reshef, Olle Ringdén, Bronwen E Shaw, Peter Shaw, Stephen R Spellman, Steven G E Marsh
PURPOSE: Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hematopoietic cell transplantation, improving survival and reducing post-transplant complications. However, most studies included relatively small numbers of patients. Here we report the findings from a large, multicenter validation study. METHODS: UHR HLA typing was available on 5,140 conventionally 10 out of 10 HLA-matched patients with malignant disease transplanted between 2008 and 2017...
April 9, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33835842/health-related-quality-of-life-with-trastuzumab-monotherapy-versus-trastuzumab-plus-standard-chemotherapy-as-adjuvant-therapy-in-older-patients-with-her2-positive-breast-cancer
#4
Naruto Taira, Masataka Sawaki, Yukari Uemura, Tsuyoshi Saito, Shinichi Baba, Kokoro Kobayashi, Hiroaki Kawashima, Michiko Tsuneizumi, Noriko Sagawa, Hiroko Bando, Masato Takahashi, Miki Yamaguchi, Tsutomu Takashima, Takahiro Nakayama, Masahiro Kashiwaba, Toshiro Mizuno, Yutaka Yamamoto, Hiroji Iwata, Yasuo Ohashi, Hirofumi Mukai, Takuya Kawahara
PURPOSE: We report findings on quality of life (QoL) in the RESPECT trial, which compared adjuvant trastuzumab monotherapy with trastuzumab plus chemotherapy in older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). PATIENTS AND METHODS: Patients age 70-80 years with human epidermal growth factor receptor 2-positive surgically treated breast cancer were randomly assigned to receive trastuzumab (T) or trastuzumab plus chemotherapy (T + C)...
April 9, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33835822/impact-of-a-genomic-test-on-treatment-decision-in-a-predominantly-african-american-population-with-favorable-risk-prostate-cancer-a-randomized-trial
#5
Adam B Murphy, Michael R Abern, Li Liu, Heidy Wang, Courtney M P Hollowell, Roohollah Sharifi, Patricia Vidal, Andre Kajdacsy-Balla, Marin Sekosan, Karen Ferrer, Shoujin Wu, Marlene Gallegos, Patrice King-Lee, Lisa K Sharp, Carol E Ferrans, Peter H Gann
PURPOSE: The Genomic Prostate Score (GPS), performed on biopsy tissue, predicts adverse outcome in prostate cancer (PCa) and has shown promise for improving patient selection for active surveillance (AS). However, its impact on treatment choice in high-risk populations of African Americans is largely unknown and, in general, the effect of the GPS on this difficult decision has not been evaluated in randomized trials. METHODS: Two hundred men with National Comprehensive Cancer Network very low to low-intermediate PCa from three Chicago hospitals (70% Black, 16% college graduates) were randomly assigned at diagnosis to standard counseling with or without a 12-gene GPS assay...
April 9, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33826362/excellent-outcome-for-pediatric-patients-with-high-risk-hodgkin-lymphoma-treated-with-brentuximab-vedotin-and-risk-adapted-residual-node-radiation
#6
Monika L Metzger, Michael P Link, Amy L Billett, Jamie Flerlage, John T Lucas, Belinda N Mandrell, Matthew J Ehrhardt, Nickhill Bhakta, Torunn I Yock, Alison M Friedmann, Pedro de Alarcon, Sandra Luna-Fineman, Eric Larsen, Sue C Kaste, Barry Shulkin, Zhaohua Lu, Chen Li, Susan M Hiniker, Sarah S Donaldson, Melissa M Hudson, Matthew J Krasin
PURPOSE: Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL. METHODS: Open-label, single-arm, multicenter trial for patients (age ≤ 18 years) with stage IIB, IIIB, or IV classical HL was conducted. Brentuximab vedotin replaced each vincristine in the OEPA/COPDac (vincristine, etoposide, prednisone, and doxorubicin/cyclophosphamide, vincristine, prednisone, and dacarbazine) regimen according to GPOH-HD2002 treatment group 3 (TG3); two cycles of AEPA and four cycles of CAPDac...
April 7, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33822655/predicting-outcomes-in-men-with-metastatic-nonseminomatous-germ-cell-tumors-nsgct-results-from-the-igcccg-update-consortium
#7
Silke Gillessen, Nicolas Sauvé, Laurence Collette, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A Gietema, Ugo De Giorgi, Fay H Cafferty, Aaron R Hansen, Torgrim Tandstad, Robert A Huddart, Andrea Necchi, Christopher J Sweeney, Xavier Garcia-Del-Muro, Daniel Y C Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene Negaard, Christian Fankhauser, Jonathan Shamash, David J Vaughn, Cora N Sternberg, Axel Heidenreich, Jörg Beyer
PURPOSE: The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. MATERIALS AND METHODS: Data on 9,728 men with metastatic nonseminomatous germ cell tumors treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Europe, North America, and Australia...
April 6, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33822650/the-randomized-ambora-trial-impact-of-pharmacological-pharmaceutical-care-on-medication-safety-and-patient-reported-outcomes-during-treatment-with-new-oral-anticancer-agents
#8
Pauline Dürr, Katja Schlichtig, Carolin Kelz, Birgit Deutsch, Renke Maas, Michael J Eckart, Jochen Wilke, Harald Wagner, Kerstin Wolff, Caroline Preuß, Valeska Brückl, Norbert Meidenbauer, Christian Staerk, Andreas Mayr, Rainer Fietkau, Peter J Goebell, Frank Kunath, Matthias W Beckmann, Andreas Mackensen, Markus F Neurath, Marianne Pavel, Frank Dörje, Martin F Fromm
PURPOSE: Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer therapy. However, considerable challenges regarding medication safety of oral anticancer drugs have been reported. Randomized, controlled, multicenter studies on the impact of intensified clinical pharmacological/pharmaceutical care on patient safety and patient treatment perception are lacking. METHODS: Patients were eligible for the randomized, multicenter AMBORA study, if they were newly started on any of the oral anticancer drugs approved in 2001 or later without restriction to certain tumor entities...
April 6, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33822640/treatment-of-pediatric-adrenocortical-carcinoma-with-surgery-retroperitoneal-lymph-node-dissection-and-chemotherapy-the-children-s-oncology-group-arar0332-protocol
#9
Carlos Rodriguez-Galindo, Mark D Krailo, Emilia M Pinto, Farzana Pashankar, Christopher B Weldon, Li Huang, Eliana M Caran, John Hicks, M Beth McCarville, David Malkin, Jonathan D Wasserman, Antonio G de Oliveira Filho, Michael P LaQuaglia, Deborah A Ward, Gerard Zambetti, Maria J Mastellaro, Alberto S Pappo, Raul C Ribeiro
PURPOSE: Adrenocortical carcinoma (ACC) is a rare aggressive pediatric malignancy with distinct biology. Its treatment follows the principles developed for adults; pediatric-specific studies are scarce. PATIENTS AND METHODS: Prospective single-arm risk-stratified interventional study. Study objectives were (1) to describe the outcome of patients with stage I ACC treated with adrenalectomy alone; (2) to describe the outcome of stage II patients (completely resected > 200 cc or > 100 g) treated with adrenalectomy and retroperitoneal lymph node dissection; and (3) to describe the outcome of patients with stage III or IV treated with mitotane and chemotherapy...
April 6, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33797953/drugging-the-master-regulator-tp53-in-cancer-mission-possible
#10
Giovanni Blandino
No abstract text is available yet for this article.
April 2, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33797939/wee1-inhibition-in-recurrent-serous-uterine-cancer-science-paving-the-way-in-a-challenging-disease
#11
EDITORIAL
Ainhoa Madariaga, Amit M Oza
No abstract text is available yet for this article.
April 2, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33797935/inhibition-of-kit-tyrosine-kinase-activity-two-decades-after-the-first-approval
#12
Lillian R Klug, Christopher L Corless, Michael C Heinrich
No abstract text is available yet for this article.
April 2, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33793318/reply-to-k-ando-et-al
#13
Joseph A Sparano, Michael R Crager, Gong Tang, Robert J Gray, Salomon M Stemmer, Steven Shak
No abstract text is available yet for this article.
April 1, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33793299/palbociclib-for-residual-high-risk-invasive-hr-positive-and-her2-negative-early-breast-cancer-the-penelope-b-trial
#14
Sibylle Loibl, Frederik Marmé, Miguel Martin, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole McCarthy, Mireia Melé Olivé, Karen Gelmon, José García-Sáenz, Catherine M Kelly, Toralf Reimer, Masakazu Toi, Hope S Rugo, Carsten Denkert, Michael Gnant, Andreas Makris, Maria Koehler, Cynthia Huang-Bartelett, Maria Jose Lechuga Frean, Marco Colleoni, Gustavo Werutsky, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Gunter von Minckwitz
PURPOSE: About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) will relapse. Thus, additional therapy is needed. Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor demonstrating efficacy in the metastatic setting. PATIENTS AND METHODS: PENELOPE-B (NCT01864746) is a double-blind, placebo-controlled, phase III study in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer without a pathological complete response after taxane-containing NACT and at high risk of relapse (clinical pathological staging-estrogen receptor grading score ≥ 3 or 2 and ypN+)...
April 1, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33793293/what-is-the-optimal-model-to-estimate-the-benefits-of-chemotherapy-in-patients-with-hormone-receptor-positive-her2-negative-node-negative-breast-cancer
#15
LETTER
Kenju Ando, Akihiko Shimomura, Kenichi Yoshimura, Yukino Kawamura, Chikako Shimizu
No abstract text is available yet for this article.
April 1, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33793292/a-small-cemetery
#16
Michael Slade
No abstract text is available yet for this article.
April 1, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33780288/mutations-in-brca1-2-and-other-panel-genes-in-patients-with-metastatic-breast-cancer-association-with-patient-and-disease-characteristics-and-effect-on-prognosis
#17
Peter A Fasching, Siddhartha Yadav, Chunling Hu, Marius Wunderle, Lothar Häberle, Steven N Hart, Matthias Rübner, Eric C Polley, Kun Y Lee, Rohan D Gnanaolivu, Peyman Hadji, Hanna Hübner, Hans Tesch, Johannes Ettl, Friedrich Overkamp, Michael P Lux, Arif B Ekici, Bernhard Volz, Sabrina Uhrig, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Erik Belleville, Michael Untch, Hans-Christian Kolberg, Matthias W Beckmann, André Reis, Arndt Hartmann, Wolfgang Janni, Pauline Wimberger, Florin-Andrei Taran, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss, Andreas D Hartkopf, Fergus J Couch
PURPOSE: Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS: Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes...
March 29, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33780274/patient-reported-outcomes-in-patients-with-pik3ca-mutated-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer-from-solar-1
#18
Eva Maria Ciruelos, Hope S Rugo, Ingrid A Mayer, Christelle Levy, Frédéric Forget, Juan Ignacio Delgado Mingorance, Tamar Safra, Norikazu Masuda, Yeon Hee Park, Dejan Juric, Pierfranco Conte, Mario Campone, Sibylle Loibl, Hiroji Iwata, Xiaolei Zhou, Jinhee Park, Antonia Ridolfi, Ines Lorenzo, Fabrice André
PURPOSE: In the phase III SOLAR-1 trial (NCT02437318), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA )-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. We assessed health-related quality of life using patient-reported outcome measures in these patients...
March 29, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33780268/caregiver-exclusion-in-the-age-of-covid-fighting-cancer-with-half-the-team
#19
Christine Alewine, Mehwish Ahmad, Rachel Shea
No abstract text is available yet for this article.
March 29, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33769862/correlative-biomarker-analysis-of-intrinsic-subtypes-and-efficacy-across-the-monaleesa-phase-iii-studies
#20
Aleix Prat, Anwesha Chaudhury, Nadia Solovieff, Laia Paré, Débora Martinez, Nuria Chic, Olga Martínez-Sáez, Fara Brasó-Maristany, Agnes Lteif, Tetiana Taran, Naveen Babbar, Fei Su
PURPOSE: The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We evaluated the association of intrinsic subtypes with progression-free survival (PFS) in the MONALEESA trials. METHODS: A retrospective and exploratory PAM50-based analysis of tumor samples from the phase III MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials was undertaken...
March 26, 2021: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"